SAN DIEGO, November 11, 2025 — Leads & Copy — Daré Bioscience, Inc. (NASDAQ: DARE) will host a live webinar on Monday, November 17, 2025, featuring sexual health and menopause clinicians Dr. Sheryl Kingsberg and Dr. Jim Simon, to discuss the DARE to PLAY™ difference.
The webinar, titled “The DARE to PLAY™ Difference,” is scheduled for 12:00 p.m. ET. Registration and access are available through https://cvent.me/KO1obd.
DARE to PLAY™ Sildenafil Cream is a topical sildenafil formulation designed for women to enhance genital blood flow and arousal response. Clinical data supports the formulation, demonstrating increased genital blood flow within 10 to 15 minutes of application and improvements in arousal sensations based on clinically validated and FDA-reviewed endpoints.
The upcoming commercial availability of DARE to PLAY™ through a 503B outsourcing facility will mark the first time a topical sildenafil formulation manufactured in accordance with cGMP requirements and supported by clinical data will be accessible to healthcare providers and their patients.
Dr. Sheryl Kingsberg, Division Chief of Behavioral Medicine at University Hospitals MacDonald Women’s Hospital and Professor at Case Western Reserve University, specializes in female sexual disorders, menopause, pregnancy and postpartum mood disorders, and psychological aspects of infertility.
Dr. James Simon, Clinical Professor at The George Washington University, focuses on complicated gynecology, sexual medicine for men and women, and menopause at his private practice, IntimMedicine Specialists®.
Webinar participants can also join the product alert list to be notified when DARE to PLAY™ Sildenafil Cream becomes available by prescription, expected later this year. The event is open to clinicians, investors, and women interested in science-based approaches to improving sexual response.
Daré Bioscience is focused on closing the gap in women’s health between science and real-world solutions. Every innovation is based on science and backed by peer-reviewed research, including contraception to menopause, pelvic pain to fertility, vaginal health to infectious disease, Daré is working to close critical gaps in care using science that serves her needs.
Daré leadership has been recognized on the Medicine Maker’s Power List and Endpoints News’ Women in Biopharma. Daré’s CEO has been honored as one of Fierce Pharma’s Most Influential People in Biopharma for Daré’s contributions to innovation and advocacy in the women’s health space.
Daré Bioscience may announce material information about its finances, products, clinical trials, and other matters using the Investors section of its website (http://ir.darebioscience.com), SEC filings, press releases, public conference calls and webcasts, and social media channels such as X (@SabrinaDareCEO and @DareBioscience).
Daré Bioscience cautions that all statements other than historical facts in the release are forward-looking and subject to risks and uncertainties, including reliance on third parties, market acceptance, and regulatory policies.
Daré Bioscience Investor Relations
innovations@darebioscience.com
Source: Daré Bioscience, Inc.
